Olaparib API Market Growth reliant on Capacity Expansion, Regulatory Approvals of Key Drug Candidates

Increased frequencies of debilitating cancers spurring enhanced R&D, prompting governments to sanction studies and clear regulatory bottlenecks

Fact.MR, Rockville MD: The olaparib API market study currently being conducted by Fact.MR forecasts a relatively high growth trajectory through FY 2021-22, amid accelerating cancer treatment research pace by prominent pharmaceutical giants. The market experienced a blip amidst the COVID-19 pandemic crisis, with data exhibiting a 60% decline in new clinical trials. However, a resurgence is being experienced as supply chains revert to normal, heightening expansion prospects.

According to Fact.MR, the olaparib API market is interspersed with a multitude of investments, including development of drug candidates to capacity expansion initiatives. For instance, global pharmaceutical giant Seqens launched a US$ 35 million specialty production unit at its Villeneuve-la-Garenne site in France in 2020 for this purpose. Additionally, regulatory approvals are playing an imperative role in defining the market’s success.

Recently, in September 2020, the European Medicines Agency (EMA) recommended approval for AstraZeneca’s Lynparza candidate, an olaparib API for treating prostate cancer and subsequent first-line maintenance for an advanced form of ovarian cancer. The approval followed a series of positive regulatory updates, which the company developed in conjunction with Merck & Co. Inc., expected to provide significant stimulus to growth.

“Prominent manufacturers are expected to acquire lucrative gains across key pharmaceutical hubs, including India, which is a leader in the Asia-Pacific API market, and China, which is its main competitor. Collectively, the two nations will open highly lucrative revenue streams,” says the Fact.MR analyst.  

Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=5279

Key Takeaways from Fact.MR’s Olaparib API Market Study

  • By indication, breast cancer is likely to attract huge investments, attributed to its high prevalence
  • Pharmaceutical companies to be the primary olaparib API end-users amid constant drug development initiatives
  • US to be a lucrative olaparib API market, attributed to the presence of a robust pharmaceutical research network
  • Recent approvals by the National Institute of Health and Care Excellence for ovarian cancer to stimulate sales in the UK
  • Top-notch pharmaceutical research capacities to bolster German olaparib API market growth prospects
  • France to experience high growth amid planned capacity expansion programs by key pharmaceutical giants
  • China & India to cement their dominance in the global olaparib API market

Olaparib API Market- Prominent Drivers

  • High incidence of prostate, breast and ovarian cancers are stimulating olaparib API market growth
  • Increasing regulatory approvals by relevant authorities is assisting manufacturers in establishing their production units across key regions
  • High presence of contract manufacturers due to the voluminous nature of API products likely to drive market growth

Olaparib API Market- Key Restraints

  • Documented side-effects, including reduction in platelet count and musculoskeletal pain, are limiting uptake
  • Preference for alternative cancer treatments sans medicines is likely to restrain future olaparib API sales

Discover more about the olaparib API market with figures and data tables, along with the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/5279/olaparib-api-market

Competitive Landscape

According to Fact.MR, the following pharmaceutical players are active in the olaparib API landscape: Pfizer Inc., AstraZeneca Plc, Novartis AG, MSN Laboratories Pvt. Ltd., ALP Pharm Beijing Co. Ltd., ScinoPharm Taiwan Ltd., Transo-Pharm USA LLC., Exelixis Inc. and Alembic Pharmaceuticals Ltd. among others.

Launching new drug formulations, conducting extensive R&D and capacity expansion are some prominent expansion measures adopted by the aforementioned players. In December 2020, AstraZeneca Plc. and MSD’s Lynparza (olaparib) was approved for treatment in Japan for advanced ovarian, prostate and pancreatic cancers. These approvals authorize usage for maintenance treatment post-bevacizumab administration for all three cancers.

In March 2021, Exelixis Inc. collaborated with WuXi Biologics for an exclusive license agreement supporting the continued expansion of Exelixis’ oncology biologics pipeline. The initiative is poised to help the company build out its pipeline behind CABOMETYX® (cabozantinib), its flagship product, along with olaparib APIs.

More Insights on the Olaparib API Market

Fact.MR, in its new offering, brings to fore an unbiased analysis of the global olaparib API market, presenting historical demand data (2016-2020) and forecast statistics for the period, 2021-2031. The study divulges compelling insights on the oaparib API market based on indication (ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and others) and end-user (contract manufacturing organizations (CMOs), contract developers & manufacturing organizations (CDMOs) and pharmaceutical companies) across eight major regions (North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, China, Japan and Middle East & Africa).

Request For No-Obligation Table Of Content


Explore Fact.MR’s Coverage on the Healthcare Domain

Medical Suction Devices Market: A recent study by Fact.MR on the medical suction devices market offers a 10-year forecast. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players associated with the manufacturing of medical suction devices.

Microdermabrasion Devices Market: A detailed assessment of microdermabrasion devices value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report published by Fact.MR on this subject. A list of prominent companies operating in the microdermabrasion devices market along with their product portfolios enhances the reliability of this comprehensive research study.

Bioengineered Protein Drugs Market: The study on the bioengineered protein drugs market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that are driving the growth of the market. This exclusive study provides incisive insights regarding recent developments in the bioengineered protein drugs market, by analyzing the historical as well as forecast data.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.    

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR

Back to news